Gilead Sciences Chairman and CEO Daniel Patrick O'Day Reports Sale of $5.33 Million in Common Shares

By Public Technologies
  • Gilead Sciences Chairman and CEO Daniel Patrick O'Day sold 30,881 common shares on Oct. 30 and Nov. 2, 2026.
  • The Oct. 30 sale covered 15,881 shares at $175.2456 per share.
  • Nov. 2 sales totaled 15,000 shares at reported prices ranging from $167.3999 to $171.0627 per share.
  • O'Day also exercised 15,881 non-qualified stock options at $72.34 per share on Oct. 30.
  • His directly owned common stock holdings stood at 551,683 shares following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001638643-26-000038), on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.